Facebook Twitter Linkedin NASDAQ Market NewsClick here to email authorNEXT STORYKymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic DermatitisPREV STORYBasilea reports strong financial results for half-year 2020, progress in R&D portfolio and successful completion of strategic projects, despite COVID-19